Role of 12/15-lipoxygenase and its metabolites in cardiovascular diseases
Journal of Lipid Research · 2026-10 · 101172
DOI: 10.1016/j.jlr.2026.101172 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Lipid Research, 2026-10. Verfasst von Jiaqi Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325024, Zhejiang, China. Die Arbeit nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
12/15-Lipoxygenase (12/15-LOX), a key oxidoreductase enzyme, catalyzes the peroxidation of polyunsaturated fatty acids (PUFAs) including omega-6 and omega-3 fatty acids. This enzyme is expressed in multiple cell types such as macrophages, endothelial cells, and epithelial cells, where it participates in arachidonic acid (AA) metabolism through the hydroperoxidation pathway. The catalytic activity of 12/15-LOX generates bioactive lipid mediators, notably 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-hydroxyeicosatetraenoic acid (15-HETE), which serve as signaling molecules in physiological and pathological processes. Emerging evidence establishes 12/15-LOX as a critical mediator in oxidative stress and inflammatory cascades. Its pathophysiological involvement has been mechanistically linked to the pathogenesis of cardiovascular disorders, particularly through promoting atherosclerotic plaque formation, vascular endothelial dysfunction, and myocardial ischemic injury. Clinical epidemiological studies further demonstrate significant associations between 12/15-LOX activity and disease progression in atherosclerosis, essential hypertension, and acute myocardial infarction. In this review, we systematically examine the biosynthetic origin of 12/15-LOX, delineate its metabolic pathways and its pleiotropic functions in modulating inflammatory responses, redox homeostasis, and programmed cell death cascades. Furthermore, we critically evaluate emerging therapeutic strategies targeting 12/15-LOX enzymatic activity or its downstream effectors, with particular emphasis on translational opportunities for cardiovascular disease management. This synthesis aims to advance the development of precision therapies targeting the 12/15-LOX pathway in cardiometabolic disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325024, Zhejiang, China.
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, China.
- Cardiac and Vascular Center, Anhui No.2 Provincial People's Hospital, Hefei 230041, Anhui, China. Electronic address: zhoujianghua@wmu.edu.cn.
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, China. Electronic address: zhoujianghua@wmu.edu.cn.
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, China. Electronic address: liyuyu0716@163.com.
Zitieren
APA
Yu, J., Ni, W., Lin, Y., Gao, Y., Zhou, J., & Li, Y. (2026). Role of 12/15-lipoxygenase and its metabolites in cardiovascular diseases. Journal of Lipid Research, 101172. https://doi.org/10.1016/j.jlr.2026.101172
Vancouver
Yu J, Ni W, Lin Y, Gao Y, Zhou J, Li Y. Role of 12/15-lipoxygenase and its metabolites in cardiovascular diseases. Journal of Lipid Research. 2026:101172. doi:10.1016/j.jlr.2026.101172
BibTeX
@article{Yu2026,
author = {Yu, Jiaqi and Ni, Weicheng and Lin, Yuanzhen and Gao, Yanlin and Zhou, Jianghua and Li, Yuyu},
title = {Role of 12/15-lipoxygenase and its metabolites in cardiovascular diseases},
journal = {Journal of Lipid Research},
year = {2026},
pages = {101172},
doi = {10.1016/j.jlr.2026.101172}
}
EUVIMED